Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like Generation Bio Emerges With $25M and Former Sobi CEO as Its New Leader January 3, 2018 Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017 Seattle’s PhaseRx Files for Bankruptcy as it Considers Partner, Merger or Sale Options December 10, 2017
Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics September 17, 2017
Seattle’s PhaseRx Files for Bankruptcy as it Considers Partner, Merger or Sale Options December 10, 2017